BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Euronext:DBV; NASDAQ:DBVT) 4/3/19 $70.4 $477.6 $581.6 22% Advaxis Inc. (NASDAQ:ADXS) 4/3/19 $10.0 $32.0 $16.8 -48% Pluristem Therapeutics Inc....
BioCentury | Feb 22, 2019
Company News

NASA to test Pluristem's PLX cells for space mission-related indications

...The NASA Ames Research Center will study the potential of placenta-based PLX cell therapies from Pluristem Therapeutics Inc....
...allogeneic placental-derived expanded (PLX) cells, for promoting muscle regeneration and to treat radiation-induced conditions, respectively. Pluristem Therapeutics Inc....
...Haifa, Israel NASA Ames Research Center, Moffett Field, Calif. Business: Other, Cardiovascular Sandi Wong PLX-PAD cells PLX-RAD cells (PLX-R18) Pluristem Therapeutics Inc. muscle...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...can commercialize the product and take it to patients.” Christopher Anzalone, Arrowhead Stem cell company Pluristem Therapeutics Inc....
...SIX:NOVN), Basel, Switzerland Novelion Therapeutics Inc. (NASDAQ:NLVN), Vancouver, Canada Orchard Therapeutics Ltd. (NASDAQ:ORTX), London, U.K. Pluristem Therapeutics Inc....
...NASDAQ:PTCT), South Plainfield, N.J. Valneva SE (Euronext:VLA), Lyon, France Erin McCallister, Senior Editor Alkahest Inc. Arrowhead Pharmaceuticals Inc. ImmusanT Inc. Pluristem Therapeutics Inc. Valneva...
BioCentury | Oct 19, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

...charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc....
...trial for CLI. The allogeneic, placental-derived expanded (PLX) cells have Fast Track designation from FDA. Pluristem Therapeutics Inc....
...NASDAQ:PSTI; Tel Aviv:PSTI), Haifa, Israel WideTrial Inc., San Francisco, Calif. Business: Other, Cardiovascular Elizabeth S. Eaton PLX-PAD cells Pluristem Therapeutics Inc. cost...
BioCentury | Oct 18, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

...charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc....
...CLI. The allogeneic, placental-derived expanded (PLX) cells have Fast Track designation from FDA. Elizabeth S. Eaton PLX-PAD cells Pluristem Therapeutics Inc. expanded...
BioCentury | Feb 16, 2018
Product R&D

Banking on the placenta

...abundant, natural source of tissues that can be transferred allogeneically. According to BioCentury’s BCIQ database, Pluristem Therapeutics Inc....
...Longevity Inc., San Diego, Calif. NantKwest Inc. (NASDAQ:NK), San Diego, Calif. PepsiCo (NASDAQ:PEP), Purchase, N.Y. Pluristem Therapeutics Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...A) 11/1/17 $8.0 NA $25.8 NA Intellia Therapeutics Inc. (NASDAQ:NTLA) 11/1/17 $150.0 $1,016.1 $813.7 -20% Pluristem Therapeutics Inc....
BioCentury | Jul 7, 2017
Financial News

Pluristem's deal with Chinese investor terminated

...On June 20, Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) disclosed that plans had been terminated for the company...
...allogeneic, placental-derived expanded (PLX) cells. Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI), Haifa, Israel Business: Cardiovascular Mary Romeo PLX cells PLX-PAD cells Pluristem Therapeutics Inc....
BioCentury | Jun 23, 2017
Financial News

Pluristem's deal with Chinese investor falls through

...company's shares have gained $0.07 to $1.39 on NASDAQ and added NIS18.50 to NIS475.10. Paul Bonanos PLX-PAD cells Pluristem Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...Inc. (NASDAQ:OCUL) 1/24/17 $25.0 $201.3 $266.9 33% Affimed N.V. (NASDAQ:AFMD) 1/20/17 $19.2 $79.0 $99.5 26% Pluristem Therapeutics Inc....
Items per page:
1 - 10 of 97
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Euronext:DBV; NASDAQ:DBVT) 4/3/19 $70.4 $477.6 $581.6 22% Advaxis Inc. (NASDAQ:ADXS) 4/3/19 $10.0 $32.0 $16.8 -48% Pluristem Therapeutics Inc....
BioCentury | Feb 22, 2019
Company News

NASA to test Pluristem's PLX cells for space mission-related indications

...The NASA Ames Research Center will study the potential of placenta-based PLX cell therapies from Pluristem Therapeutics Inc....
...allogeneic placental-derived expanded (PLX) cells, for promoting muscle regeneration and to treat radiation-induced conditions, respectively. Pluristem Therapeutics Inc....
...Haifa, Israel NASA Ames Research Center, Moffett Field, Calif. Business: Other, Cardiovascular Sandi Wong PLX-PAD cells PLX-RAD cells (PLX-R18) Pluristem Therapeutics Inc. muscle...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...can commercialize the product and take it to patients.” Christopher Anzalone, Arrowhead Stem cell company Pluristem Therapeutics Inc....
...SIX:NOVN), Basel, Switzerland Novelion Therapeutics Inc. (NASDAQ:NLVN), Vancouver, Canada Orchard Therapeutics Ltd. (NASDAQ:ORTX), London, U.K. Pluristem Therapeutics Inc....
...NASDAQ:PTCT), South Plainfield, N.J. Valneva SE (Euronext:VLA), Lyon, France Erin McCallister, Senior Editor Alkahest Inc. Arrowhead Pharmaceuticals Inc. ImmusanT Inc. Pluristem Therapeutics Inc. Valneva...
BioCentury | Oct 19, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

...charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc....
...trial for CLI. The allogeneic, placental-derived expanded (PLX) cells have Fast Track designation from FDA. Pluristem Therapeutics Inc....
...NASDAQ:PSTI; Tel Aviv:PSTI), Haifa, Israel WideTrial Inc., San Francisco, Calif. Business: Other, Cardiovascular Elizabeth S. Eaton PLX-PAD cells Pluristem Therapeutics Inc. cost...
BioCentury | Oct 18, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

...charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc....
...CLI. The allogeneic, placental-derived expanded (PLX) cells have Fast Track designation from FDA. Elizabeth S. Eaton PLX-PAD cells Pluristem Therapeutics Inc. expanded...
BioCentury | Feb 16, 2018
Product R&D

Banking on the placenta

...abundant, natural source of tissues that can be transferred allogeneically. According to BioCentury’s BCIQ database, Pluristem Therapeutics Inc....
...Longevity Inc., San Diego, Calif. NantKwest Inc. (NASDAQ:NK), San Diego, Calif. PepsiCo (NASDAQ:PEP), Purchase, N.Y. Pluristem Therapeutics Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...A) 11/1/17 $8.0 NA $25.8 NA Intellia Therapeutics Inc. (NASDAQ:NTLA) 11/1/17 $150.0 $1,016.1 $813.7 -20% Pluristem Therapeutics Inc....
BioCentury | Jul 7, 2017
Financial News

Pluristem's deal with Chinese investor terminated

...On June 20, Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) disclosed that plans had been terminated for the company...
...allogeneic, placental-derived expanded (PLX) cells. Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI), Haifa, Israel Business: Cardiovascular Mary Romeo PLX cells PLX-PAD cells Pluristem Therapeutics Inc....
BioCentury | Jun 23, 2017
Financial News

Pluristem's deal with Chinese investor falls through

...company's shares have gained $0.07 to $1.39 on NASDAQ and added NIS18.50 to NIS475.10. Paul Bonanos PLX-PAD cells Pluristem Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...Inc. (NASDAQ:OCUL) 1/24/17 $25.0 $201.3 $266.9 33% Affimed N.V. (NASDAQ:AFMD) 1/20/17 $19.2 $79.0 $99.5 26% Pluristem Therapeutics Inc....
Items per page:
1 - 10 of 97